Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Accumulated Expenses (2019 - 2025)

aTYR PHARMA's Accumulated Expenses history spans 7 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 4.25% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 4.25%, while the annual FY2025 figure was $9.8 million, 4.25% up from the prior year.
  • Accumulated Expenses reached $9.8 million in Q4 2025 per ATYR's latest filing, down from $10.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.8 million in Q2 2023 to a low of $2.4 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $7.1 million, with a median of $8.4 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: plummeted 30.51% in 2022, then surged 247.08% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $4.0 million in 2021, then tumbled by 30.51% to $2.8 million in 2022, then fell by 2.7% to $2.7 million in 2023, then soared by 247.08% to $9.4 million in 2024, then rose by 4.25% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Accumulated Expenses are $9.8 million (Q4 2025), $10.2 million (Q3 2025), and $10.3 million (Q2 2025).